Lixte Biotech Appoints New Chief Medical Officer
Ticker: LIXT · Form: 8-K · Filed: Sep 4, 2025 · CIK: 1335105
Sentiment: neutral
Topics: management-change, biotechnology, personnel
Related Tickers: LIXT
TL;DR
Lixte Biotech names Dr. Jack Greene as new CMO to push cancer drug development.
AI Summary
Lixte Biotechnology Holdings, Inc. announced on September 3, 2025, the appointment of Dr. John B. "Jack" Greene as Chief Medical Officer. Dr. Greene, previously a consultant for the company, brings extensive experience in clinical development and regulatory affairs. This appointment is part of Lixte's ongoing efforts to advance its pipeline of cancer therapeutics.
Why It Matters
The appointment of a new Chief Medical Officer signals a strategic move by Lixte Biotechnology to bolster its leadership in clinical development, potentially accelerating the progress of its cancer drug candidates.
Risk Assessment
Risk Level: medium — Biotechnology companies often carry medium risk due to the inherent uncertainties in drug development and regulatory approval processes.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant
- Dr. John B. "Jack" Greene (person) — Appointed Chief Medical Officer
- September 3, 2025 (date) — Date of earliest event reported
- September 1, 2025 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Lixte Biotechnology Holdings, Inc.?
Dr. John B. "Jack" Greene has been appointed as the new Chief Medical Officer.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is September 3, 2025, with the earliest event occurring on September 1, 2025.
What is the company's ticker symbol?
The filing does not explicitly state the ticker symbol, but the context suggests it is LIXT.
In which state was Lixte Biotechnology Holdings, Inc. incorporated?
Lixte Biotechnology Holdings, Inc. was incorporated in Delaware.
What is the primary business of Lixte Biotechnology Holdings, Inc. according to the SIC code?
According to the Standard Industrial Classification (SIC) code, the company is in the Pharmaceutical Preparations industry.
Filing Stats: 1,088 words · 4 min read · ~4 pages · Grade level 11.4 · Accepted 2025-09-03 17:44:18
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The NASDAQ Stock Mar
- $150,000 — ment, the Company will pay Mr. Stazzone $150,000 annually, to be paid monthly. Such comp
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex99-1.htm (EX-99.1) — 16KB
- 0001641172-25-026448.txt ( ) — 276KB
- lixt-20250903.xsd (EX-101.SCH) — 4KB
- lixt-20250903_def.xml (EX-101.DEF) — 26KB
- lixt-20250903_lab.xml (EX-101.LAB) — 36KB
- lixt-20250903_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2025 LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Registrant) By: /s/ Geordan Pursglove Geordan Pursglove Chairman of the Board and Chief Executive Officer INDEX TO EXHIBITS Exhibit No. Description 99.1 Press Release regarding the appointment of two new Board Members and a new Chief Financial Officer dated September 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)